Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Brain-Specific Quantification of Somatostatin Receptor Expression: SUV_max and SUVR_sss as Quantitative Correlates of the Krenning Score in Meningioma.","authors":"Valentina Marulanda-Corzo, Michael Farid, Trevor Hill, Arsalan Haghdel, Andres Ricaurte-Fajardo, Hannah G Otis, Kellen Vo Vu, Arindam RoyChoudhury, Michelle Roytman, Andrew Brandmaier, Rajiv S Magge, Derek R Johnson, Joseph R Osborne, Haley K Perlow, Tugce Kutuk, Joshua Palmer, Jana Ivanidze","doi":"10.2967/jnumed.126.272351","DOIUrl":"https://doi.org/10.2967/jnumed.126.272351","url":null,"abstract":"<p><p>Somatostatin receptor type 2 is highly expressed in meningiomas and can be quantified using [⁶⁸Ga]Ga-DOTATATE PET. The Krenning score, originally developed for [¹¹¹In]In-octreotide scintigraphy, remains the standard visual grading system for somatostatin receptor expression and is widely used to guide eligibility for peptide receptor radionuclide therapy. However, visual grading may not optimally translate to intracranial disease. This study evaluated the relationship between brain-specific quantitative PET parameters-SUV_max and SUV ratio normalized to the superior sagittal sinus (SUVR_sss)-and the Krenning score in meningioma. <b>Methods:</b> This single-institution retrospective study included 44 patients (70 meningiomas) who underwent clinical vertex-to-thigh [⁶⁸Ga]Ga-DOTATATE PET/CT. Quantitative parameters (SUV_max, SUVR_sss, lesion size) were extracted from coregistered PET and MR images. Spearman rank correlation analysis was performed to assess associations between imaging variables and Krenning score. Differences in quantitative PET parameters across Krenning categories were evaluated using Kruskal-Wallis test and Holm-Bonferroni-corrected Mann-Whitney <i>U</i> test. Receiver-operating-characteristic curve analysis using the Youden <i>J</i> index identified optimal cutoffs for clinically relevant thresholds (Krenning score of <3 vs. ≥3 and 3 vs. 4). <b>Results:</b> SUVR_sss and SUV_max were strongly correlated with the Krenning score (SUVR_sss: Spearman ρ = 0.70; 95% CI, 0.55-0.82; SUV_max: Spearman ρ = 0.77; 95% CI, 0.64-0.85; <i>P</i> < 0.0001). PET parameters differed significantly across Krenning categories (all <i>P</i> < 0.001). SUVR_sss optimal thresholds were 9.00 (area under the curve [AUC], 0.86; 95% CI, 0.74-0.96) for Krenning scores of 2 versus 3 and 29.84 (AUC, 0.98; 95% CI, 0.93-1.00) for Krenning scores of 3 versus 4. SUV_max optimal thresholds were 7.20 (AUC, 0.92; 95% CI, 0.84-0.99) and 30.70 (AUC, 0.98; 95% CI, 0.95-1.00), respectively. <b>Conclusion:</b> SUVR_sss and SUV_max are complementary quantitative correlates of Krenning scores 2-4 in [⁶⁸Ga]Ga-DOTATATE PET-visible, MRI-measurable meningiomas. Brain-only PET evaluation may provide an alternative to liver- and spleen-based visual grading and reduce the need for whole-body imaging in selected settings. Receiver-operating-characteristic curve-derived SUV thresholds correspond to Krenning scores used for eligibility for treatment with peptide receptor radionuclide therapy, supporting further evaluation of quantitative PET parameters for theranostic decision-making for patients with meningioma.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Test-Retest Repeatability of [¹⁸F]FDG Uptake by Solid Tumors on PET/MRI: A Prospective, Multicenter Study Using the QIBA Protocol.","authors":"Tyler J Fraum, Gianmarco Calderara, Hongyu An, Hamdi Mahdjoub, Peder E Z Larson, Vahid Ravanfar, Richard Laforest, Thomas A Hope","doi":"10.2967/jnumed.126.272891","DOIUrl":"https://doi.org/10.2967/jnumed.126.272891","url":null,"abstract":"<p><p>Prior oncologic PET/MRI repeatability studies have been limited by single-center designs, small cohorts, or select patient populations. Our primary aim was to estimate the test-retest repeatability of uptake metrics on [¹⁸F]FDG PET/MRI studies across a variety of cancer types. A secondary aim was to assess the impact of intersession μ-map variability on repeatability. <b>Methods:</b> In this prospective study involving 2 institutions with different PET/MRI scanners, subjects completing standard-of-care [¹⁸F]FDG PET/CT or MRI examinations were recruited to undergo 2 research [¹⁸F]FDG PET/MRIs (i.e., test and retest) within a 1-9 d period per Quantitative Imaging Biomarker Alliance specifications. Enrollment required at least 1 measurable lesion (long axis ≥ 2 cm, known or expected SUV_max ≥ 4.0) and no active oncologic therapy. SUV_max and SUV_peak were extracted from measurable lesions (1-5 per subject). At site 1, attenuation-coefficient maps (i.e., μ-maps) were inspected for substantial differences across sessions. Additionally, at site 1, the retest μ-map was coregistered to the test μ-map, and the PET attenuation-correction process was repeated for the test session based on the retest μ-map. Intersession repeatability was assessed via Bland-Altman plots, and within-subject coefficients of variation (wCVs) were calculated. <b>Results:</b> At site 1, 10 subjects with 11 measurable lesions were analyzed, and the wCVs for SUV_max and SUV_peak were 12.3% and 9.6%, respectively. At site 2, 11 subjects with 30 measurable lesions were analyzed, and the wCVs for SUV_max and SUV_peak were 9.5% and 8.8%, respectively. At site 1, repeating attenuation correction of the test PET data with the retest μ-map slightly improved repeatability, reducing the wCV to 10.1% for SUV_max and to 9.1% for SUV_peak For 8 of 11 lesions at site 1, the μ-map substitution altered the test-retest change by less than 5%, with no appreciable intersession μ-map differences or artifacts. <b>Conclusion:</b> The test-retest repeatability of SUV_max among hypermetabolic lesions on [¹⁸F]FDG PET/MRI, using data from 2 scanner models, was similar to the Quantitative Imaging Biomarker Alliance's wCV benchmark of 10%-12% for [¹⁸F]FDG PET/CT. Intersession μ-map variations had minimal negative impact on repeatability.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Function Decline After ¹⁷⁷Lu-PSMA-617 Versus Taxane-Based Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Propensity Score Analysis.","authors":"Natasha Sheheryar, Yalda Nikanpour, Sandhya Manohar, Dan Childs, Gokce Belge Bilgin, Robert McDonald, Jennifer McDonald, Matt P Thorpe, Geoffrey B Johnson","doi":"10.2967/jnumed.126.272551","DOIUrl":"10.2967/jnumed.126.272551","url":null,"abstract":"<p><p>We conducted a study to determine the effects of ¹⁷⁷Lu-PSMA-617 treatment on renal function decline in patients with metastatic castration-resistant prostate cancer (mCRPC) shortly after treatment and over long-term follow-up. <b>Methods:</b> The study used comparative and counterfactual analysis. Patients were eligible for inclusion if they received at least 3 but no more than 6 cycles of ¹⁷⁷Lu-PSMA-617 with androgen-deprivation therapy or completed 6 cycles of docetaxel with or without androgen-deprivation therapy. Further, the availability of serum creatinine and estimated glomerular filtration rate (eGFR) measurements within a 30-d window for each treatment cycle was required. A decline in eGFR of greater than 3 mL/min/1.73 m²/year was assessed by comparing baseline values with the posttreatment eGFR and the last available follow-up eGFR. The incidence of eGFR decline was compared between patients who received radiopharmaceutical therapy (RPT) and those who received chemotherapy after 1:1 matching, inverse probability weighting, and weighting by odds method to reduce intergroup selection bias with an additional counterfactual analysis of patients who received both treatments sequentially. <b>Results:</b> After propensity score adjustment using established risk factors for renal function decline, there was no difference in renal function deterioration in early posttreatment (6 mo after treatment) between patients who received RPT and those who received chemotherapy (median eGFR decreased from 82 to 80 mL/min/1.73 m² within the RPT group, <i>P</i> = 0.49 in both treatment groups). During long-term follow-up, the overall incidence of renal function decline increased in both groups (<i>P</i> = 0.044, median eGFR fall from 82 to 72 mL/min/1.73 m² in the RPT-treated group). Stratified analyses demonstrated no change among patients with preserved baseline renal function (<i>P</i> = 0.49), whereas patients with chronic kidney disease exhibited a significantly greater decline in renal function (<i>P</i> = 0.0023). Renal function remained stable over 6 cycles of RPT compared with 6 cycles of chemotherapy within the same patients. <b>Conclusion:</b> After adjustment of presumed risk factors, renal function decline was most prevalent in patients with lower baseline renal function. Renal function decline in patients with mCRPC, who are already susceptible to compromised renal function, may not be solely caused by ¹⁷⁷Lu-PSMA-617 therapy.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Simple Guide For Patients About Radiation Safety.","authors":"Alice Fialho Viana, Sugandha Dureja","doi":"10.2967/jnumed.126.273428","DOIUrl":"https://doi.org/10.2967/jnumed.126.273428","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Residual ¹⁷⁷Lu Activity Complicates Interpretation of Day 3 SPECT in OPTIMAL-PSMA\".","authors":"Louise Emmett, Katharina Lückerath","doi":"10.2967/jnumed.126.273643","DOIUrl":"https://doi.org/10.2967/jnumed.126.273643","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual ¹⁷⁷Lu Activity Complicates Interpretation of Day 3 SPECT in OPTIMAL-PSMA.","authors":"Yan Huang, Yang Liu","doi":"10.2967/jnumed.126.273626","DOIUrl":"https://doi.org/10.2967/jnumed.126.273626","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-Cell Mass and Function, Pancreatic Volume, and Fat Differences Between Short- and Long-Duration Type 1 Diabetes: A Detailed PET/CT Imaging Study.","authors":"Sevilay Tokgöz, Pleun de Groen, Theodorus J P Jansen, Coco M Fuhri Snethlage, Marti Boss, Hajime Yamazaki, Max Nieuwdorp, Martin Gotthardt, Nordin M J Hanssen, Rick I Meijer","doi":"10.2967/jnumed.126.272915","DOIUrl":"https://doi.org/10.2967/jnumed.126.272915","url":null,"abstract":"<p><p>People with recent-onset diabetes often have preserved C-peptide production, which tends to decline during the first 7 y after diagnosis and stabilizes thereafter. Whether this holds true for β-cell mass is unknown. In this pooled post hoc analysis, we aimed to investigate total β-cell mass in individuals with short- and long-duration type 1 diabetes. <b>Methods:</b> Data of 16 individuals with short- (<7 y) and 10 with long-duration type 1 diabetes (≥7 y) who underwent [⁶⁸Ga]Ga-NODAGA-exendin-4 PET/CT and mixed-meal tolerance test were used to determine total β-cell mass and function, respectively. Intrapancreatic fat deposition and pancreatic volume were derived from CT. <b>Results:</b> Total β-cell mass was higher in individuals with short-duration type 1 diabetes compared with those with long-duration type 1 diabetes (4.4 ± 1.8 vs. 2.8 ± 1.3 kBq/MBq, <i>P</i> = 0.012). Larger pancreatic volume, lower intrapancreatic fat deposition, and higher β-cell function were observed in individuals with short-duration type 1 diabetes compared with the long-duration group. Total β-cell mass positively correlated with β-cell function (<i>r</i> = 0.46, <i>P</i> = 0.019) and pancreatic volume (<i>r</i> = 0.91, <i>P</i> < 0.0001) and inversely correlated with body mass index (<i>r</i> = -0.61, <i>P</i> = 0.0009). <b>Conclusion:</b> This study offers insights in the potential of imaging markers together with function tests to monitor disease progression and may offer valuable information for the timing to restore β-cell function or to slow down β-cell destruction.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-Labeled Dimeric Cyclic Peptide for Nectin-4-Targeted PET Imaging: From Preclinical Evaluation to First-in-Human Imaging in Breast Cancer.","authors":"Shushan Ge, Jihui Li, Jinyu Shi, Tongtong Jia, Dingding Ai, Junpeng Li, Shibiao Sang, Jing Lan, Bin Zhang, Shengming Deng","doi":"10.2967/jnumed.126.273306","DOIUrl":"https://doi.org/10.2967/jnumed.126.273306","url":null,"abstract":"<p><p>Nectin-4 is an attractive target for molecular imaging and targeted therapy because of its overexpression in multiple malignancies. We developed a nectin cell adhesion molecule 4 (nectin-4)-targeted ⁶⁸Ga-labeled dimeric cyclic peptide PET tracer, [⁶⁸Ga]Ga-TDN1, for noninvasive imaging of nectin-4 expression. <b>Methods:</b> TDN1 was generated by click chemistry to conjugate 2 nectin-4-binding bicyclic peptides and was radiolabeled with ⁶⁸Ga. Binding affinity was assessed by surface plasmon resonance. Target specificity and tumor-targeting ability were evaluated by cell uptake, blocking, small-animal PET/CT, and biodistribution studies in nectin-4-positive and nectin-4-negative tumor models. [⁶⁸Ga]Ga-TDN1 was further compared with [⁶⁸Ga]Ga-N188 in preclinical models. After preclinical evaluation, [⁶⁸Ga]Ga-TDN1 PET/CT was investigated in a pilot first-in-human study in 6 patients with breast cancer and directly compared with [¹⁸F]FDG PET/CT. <b>Results:</b> TDN1 showed high affinity for nectin-4 (<i>K</i> _D = 1.92 × 10^-10 M). In preclinical studies, [⁶⁸Ga]Ga-TDN1 showed specific uptake in nectin-4-positive cells and tumors, low uptake in nectin-4-negative models, and marked reduction in uptake under blocking conditions. Compared with [⁶⁸Ga]Ga-N188, [⁶⁸Ga]Ga-TDN1 showed higher tumor uptake and longer retention across multiple nectin-4-positive xenografts. In the pilot clinical study, [⁶⁸Ga]Ga-TDN1 was well-tolerated and showed favorable biodistribution and dosimetry. [⁶⁸Ga]Ga-TDN1 PET/CT revealed imaging performance comparable to that of [¹⁸F]FDG PET/CT for primary tumors and most nodal metastases and demonstrated higher uptake and improved lesion detection in bone and liver metastases in selected patients. [⁶⁸Ga]Ga-TDN1 was a clinically translatable nectin-4-targeted PET tracer with high affinity, favorable pharmacokinetics, and specific tumor uptake. Preclinical and pilot clinical results supported further clinical evaluation of [⁶⁸Ga]Ga-TDN1 for noninvasive imaging of nectin-4 expression, particularly for assessment of metastatic disease.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[⁸⁹Zr]Zr-DFO-EPO Imaging of Ischemia-Induced Cellular Stress.","authors":"Salvador Guillermo Castaneda-Vega, Kristin Schelling, Francesca Russo, Dominik Seyfried, Carsten Calaminus, Sandra Beer-Hammer, Ursula Kohlhofer, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Manuela Neumann, Andreas Maurer, Christian la Fougère, Bernd Nürnberg, Bernd J Pichler","doi":"10.2967/jnumed.126.272081","DOIUrl":"https://doi.org/10.2967/jnumed.126.272081","url":null,"abstract":"<p><p>Hypoxia-inducible signaling drives the expression of cytoprotective genes, including genes for erythropoietin and erythropoietin receptor (EPOr), positioning EPOr targeting as a potential biomarker of cellular stress responses. In this study, we evaluate ischemic stroke tissue in vivo using ⁸⁹Zr-labeled recombinant human erythropoietin. <b>Methods:</b> Recombinant human erythropoietin was conjugated with desferrioxamine and radiolabeled with ⁸⁹Zr ([⁸⁹Zr]Zr-DFO-EPO), and its affinity for dimeric EPOr was confirmed in vitro. Longitudinal PET and MRI were performed daily for up to 72 h after stroke in 2 ischemic stroke models: the pertussis toxin-induced stroke in mice and transient middle cerebral artery occlusion in rats. Radiotracer accumulation and distribution in the stroke region were validated by autoradiography and hematoxylin and eosin histology. Specificity to erythropoietin receptors was evaluated by competitive displacement with excess unlabeled erythropoietin. <b>Results:</b> [⁸⁹Zr]Zr-DFO-EPO showed high radiochemical purity and accumulated in ischemic regions in both stroke models. Distinct spatial uptake patterns inside the stroke region were observed between models, with border zone-predominant accumulation in rats with transient middle cerebral artery occlusion and more homogeneous uptake in mice with pertussis toxin-induced stroke, reflecting the known differences in ischemia induction and vascular pathophysiology between the models. In mice, radiotracer uptake spatially correlated with hypoxia-inducible factor 1α and erythropoietin expression. In rats, tracer uptake was verified in the histologically delimited stroke region. Dose-dependent and specific EPOr binding was confirmed in rats ex vivo as well as in human ischemic tissue. In human ischemic stroke samples, radiotracer binding followed histologic morphology, with higher uptake in structurally preserved periinfarct regions and lower uptake in necrotic infarct cores. These findings support [⁸⁹Zr]Zr-DFO-EPO PET as a proof-of-concept approach for assessment of ischemia-associated EPOr-related stress signaling. <b>Conclusion:</b> Across 2 distinct ischemic stroke models, [⁸⁹Zr]Zr-DFO-EPO revealed model-dependent uptake patterns, with periinfarct enrichment confined to focal ischemia characterized by preserved tissue architecture. Specific and displaceable binding in human ischemic stroke tissue with comparable histomorphology underscores the translational relevance of EPOr imaging as a biomarker of hypoxia-associated cellular stress.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[⁶⁸Ga]Ga-SSO120 PET/CT Imaging in Pediatric Patients with Neuroblastoma: Biodistribution and Whole-Body Radiation Dosimetry.","authors":"Leonor Teles, Rob van Rooij, Max M van Noesel, Nelleke Tolboom, Alex J Poot, Arthur J A T Braat","doi":"10.2967/jnumed.126.272321","DOIUrl":"https://doi.org/10.2967/jnumed.126.272321","url":null,"abstract":"<p><p>The clinical standard for neuroblastoma detection is based on targeting the norepinephrine transporter with [¹²³I]MIBG, which has several challenges. Imaging the somatostatin receptor (SSTR) is a strong alternative. In contrast to standard DOTATATE, SSTR antagonist imaging with [⁶⁸Ga]Ga-satoreotide trizoxetan ([⁶⁸Ga]-SSO120) can potentially improve lesion detection as it targets both active and inactive SSTRs. We present the biodistribution and radiation exposure results of [⁶⁸Ga]Ga-SSO120 PET/CT imaging in pediatric patients with neuroblastoma. <b>Methods:</b> Patients age 3-7 y with stage 4 neuroblastoma received 2 MBq/kg of [⁶⁸Ga]Ga-SSO120, followed by a 60-min dynamic scan and a static PET/CT scan. SUV normalized to lean body mass (SUL_max, SUL_mean, SUL_peak) and time-activity curves were measured for suspected lesions and various tissue compartments. Tumor-to-liver and tumor-to-blood pool ratios were calculated. Radiation doses to various organs and the total-body effective dose were computed. <b>Results:</b> Five patients underwent dynamic [⁶⁸Ga]Ga-SSO120 PET/CT scanning, with a total of 17 neuroblastoma lesions. The median administered activity was 2.5 MBq/kg (range, 2.1-2.8 MBq/kg). At 60 min postinjection, the median tumor SUL_max and SUL_peak were 4.28 (range, 1.89-18.07) and 2.71 (range, 1.23-14.77), respectively, and the median tumor-to-liver ratio was 4.05. The highest exposure was in the bladder (22.3 ± 4.3 μSv/MBq). The effective dose was 0.088 ± 0.014 mSv/MBq. <b>Conclusion:</b> [⁶⁸Ga]Ga-SSO120 PET/CT was safe in pediatric patients with neuroblastoma, with a low effective radiation dose, and detected neuroblastoma lesions with a good target-to-noise ratio. Image acquisition at 30 and 60 min postinjection seemed equivalent.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}